DDInter745 DDInter1676
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Fludarabine {u} (Compound) resembles {v} (Compound) Adenosine triphosphate
Fludarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Fludarabine {u} (Compound) binds {v} (Gene) POLA1
Fludarabine {u} (Compound) causes {v} (Side Effect) Discomfort
Fludarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Fludarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ofloxacin
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Fludarabine {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Fludarabine {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Fludarabine (Compound) resembles Adenosine triphosphate (Compound)
Fludarabine (Compound) treats hematologic cancer (Disease)
Fludarabine (Compound) binds POLA1 (Gene)
Fludarabine (Compound) causes Discomfort (Side Effect)
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Fludarabine may lead to a major life threatening interaction when taken with Natalizumab
Fludarabine may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen